Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P17 vs Humira in moderate to severe rheumatoid arthritis (with methotrexate)
2018-001690-25Phase 3Completed
- Sponsor
- Celltrion
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of RT-105 in rheumatoid arthritis (RA) (2 arms), sponsored by Celltrion. Primary endpoint: ACR20 response at Week 24. Started Aug 2018; status: completed.
02
Drugs
RT-105
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2018-001690-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001690-25.